dr. patrick m. forde on next steps after failed checkmate-026 study in nsclc
Published 7 years ago • 185 plays • Length 1:06Download video MP4
Download video MP3
Similar videos
-
2:04
dr. patrick m. forde on neoadjuvant dr. patrick m. forde on neoadjuvant nivolumab in nsclc
-
2:56
dr. patrick forde discusses 3-year checkmate 816 nsclc results at asco 2023
-
1:58
dr. heymach discusses the checkmate-026 study in lung cancer
-
2:08
dr. bunn on missed endpoint in checkmate-026 for nsclc
-
2:08
why checkmate-026 failed to show pfs improvement with nivolumab in lung cancer
-
29:46
lung cancer and immunotherapy with dr. patrick forde and oswald peterson
-
41:05
dr. patrick forde on practical benefits & clinical promise of neoadjuvant therapy in nsclc | btj-022
-
39:04
meningeal lymphatics in brain's health and disease - jonathan kipnis, phd - le&rn symposium
-
15:21
is there a link between cancer and heart disease? | nicholas leeper | ted
-
3:12
opdivo (nivolumab) the immunotherapy cancer treatment
-
27:00
pearls and pitfalls in the approach to myelopathy
-
2:17
dr. borghaei on the checkmate-227 trial in nsclc
-
1:29
dr. kelly on the toxicity profile in checkmate-227 in nsclc
-
6:24
researcher comment: the pre0505 study | patrick forde
-
6:04
checkmate 816 trial: nivolumab platinum-doublet chemotherapy vs chemo as neoadjuvant treatment...
-
18:07
mesotv | johns hopkins' dr. patrick forde speaks with us
-
3:45
firstword analyst notes: opdivo and the checkmate-026 trial – kols speak out
-
1:18
treatment strategies for non-mnsclc | patrick forde, m.b.b.ch. | esmo22 pennsylvania
-
9:54
opdivo failed in nsclc
-
6:07
interpreting the results of checkmate-227 in nsclc
-
6:13
checkmate-227: testing ipilimumab/nivolumab in nsclc
-
1:58
dr. plimack on significance of checkmate-025 trial in rcc